Retinitis Proliferans

Retinitis proliferans is an old medical term that means new, abnormal blood vessels growing on the retina. The retina is the light-sensing layer at the back of the eye. These fragile vessels grow because parts of the retina are starved of oxygen (ischemia). The growth is the body’s attempt to help, but it actually causes problems: bleeding into the eye (vitreous hemorrhage), scar tissue, and tugging that can pull the retina off (tractional retinal detachment). Today, doctors more often use the phrase “proliferative retinopathy” or “retinal neovascularization.” The most common example is proliferative diabetic retinopathy. Merriam-Webster+2NCBI+2

Doctors used the older term retinitis proliferans to describe severe eye disease where new, fragile blood vessels grow and scar on the retina. Today, we usually call this proliferative diabetic retinopathy (PDR) when it occurs from diabetes, or proliferative vitreoretinopathy (PVR) when scarring membranes grow after a retinal detachment. In both cases, the abnormal vessels and fibrous tissue can bleed, pull the retina, and cause tractional retinal detachment, threatening vision. Historically, “retinitis proliferans” was even listed as Stage V in older diabetic-retinopathy classifications. PMC+3Merriam-Webster+3PMC+3

Think of it as “abnormal vessel growth + scar tissue on the retina.” In diabetes (PDR), new vessels grow on the retina and optic disc; these vessels sit on top of the retina and into the vitreous gel, then scar and contract. In PVR after a detachment, various retinal cells form membranes on or under the retina that contract and redetach the retina. Both patterns can cause recurrent bleeding, vision loss, and retinal detachment without timely care. PMC+2Wikipedia+2

Over time, many conditions that reduce blood flow in the retina can trigger this process. In sickle cell disease, for example, special “sea-fan”-shaped vessels can form in the peripheral retina. In Eales disease (an idiopathic retinal vasculitis), inflammation and blockage of veins lead to ischemia and then new vessels. All of these are examples of “retinitis proliferans” in the historical sense—retinal neovascularization due to ischemia. EyeWiki+1

Other Names

• Proliferative retinopathy (e.g., proliferative diabetic retinopathy)

• Retinal neovascularization

• Neovascular retinopathy

• Proliferative sickle retinopathy (context-specific)

• Historical terms you may still see in older papers: “retinitis proliferans” itself; “fibrovascular proliferation”; and, in older Eales disease literature, references to retinitis proliferans on exam after recurrent bleeding. NCBI+2EyeWiki+2

Types

1) Proliferative diabetic retinopathy (PDR)
This is the classic modern example. New vessels grow on the optic disc or elsewhere on the retina when long-standing diabetes causes ischemia. These vessels bleed easily and can cause tractional retinal detachment. AAO

2) Proliferative sickle cell retinopathy (PSR)
In sickle cell disease (especially HbSC), occluded peripheral vessels lead to “sea-fan” neovascular tufts at the border of non-perfused retina, with a recognized five-stage classification. EyeWiki

3) Eales disease–related neovascularization
Idiopathic occlusive retinal vasculitis (often in young adults) causes ischemia and neovascularization with recurrent vitreous hemorrhage. EyeWiki

4) Other ischemic proliferative retinopathies
Any condition that causes chronic retinal non-perfusion can produce pathologic new vessels—this includes ocular ischemic states and certain occlusive vasculitides (see causes below). The unifying feature is ischemia-driven neovascularization. ScienceDirect

(Note: “Proliferative vitreoretinopathy (PVR)” is different—it’s scarring and membrane formation after retinal detachment surgery/tears, not new blood vessel growth. It appears in differential discussions but is not the same entity.)

Causes

1. Diabetes mellitus (PDR) – Long-term high blood sugar damages retinal vessels. Parts of the retina lose blood supply, releasing growth signals that make fragile new vessels sprout. AAO

2. Sickle cell disease (PSR) – Sickled red cells block small retinal vessels, especially in the periphery, creating sea-fan neovascularization at the border of non-perfused retina. EyeWiki

3. Eales disease – A retinal vein inflammation and occlusion syndrome (often idiopathic) that progresses from periphlebitis to ischemia to neovascularization and recurrent vitreous hemorrhage. EyeWiki

4. Retinal vein occlusion (ischemic branch or central) – A blocked vein causes widespread retinal non-perfusion; the hypoxic retina drives new vessel formation. (General proliferative retinopathy mechanism.) ScienceDirect

5. Ocular ischemic syndrome (carotid artery disease) – Severely reduced ocular blood flow can produce retinal ischemia and subsequent neovascularization. ScienceDirect

6. Retinopathy of prematurity (advanced, untreated) – In severe stages, avascular peripheral retina in premature infants becomes ischemic, leading to pathologic neovascularization. (Mechanism consistent with proliferative retinopathy.) ScienceDirect

7. Inflammatory retinal vasculitis (non-Eales) – Conditions such as idiopathic vasculitis or infection-linked vasculitis can cause occlusion and ischemia with secondary neovascularization. (Mechanism overview.) ScienceDirect

8. Tuberculosis-associated retinal vasculitis – TB can trigger periphlebitis and occlusion similar to Eales-like pictures, progressing to neovascularization. (Eales reviews discuss mycobacterial triggers.) EyeWiki

9. Sarcoidosis-related retinal vasculitis – Granulomatous vessel wall disease can reduce perfusion and promote new vessels. (Mechanism consistent with proliferative retinopathy.) ScienceDirect

10. Severe chronic anemia or hypoxia – Reduced oxygen delivery can worsen retinal ischemia in predisposed eyes, encouraging neovascularization. (Mechanistic context of ischemia-driven neovascularization.) ScienceDirect

11. Radiation retinopathy – After ocular/periocular radiotherapy, delayed capillary loss and ischemia can result in proliferative changes. (Mechanism overview.) ScienceDirect

12. High-altitude or systemic hypoxemia (contributory) – Lower oxygen availability can aggravate ischemic drive in susceptible retinas. (Mechanism overview.) ScienceDirect

13. Traumatic peripheral retinal ischemia – Rarely, severe trauma with vascular damage can lead to ischemia and later neovascularization. Chorioretinitis sclopetaria literature notes older terms overlapping with “retinitis proliferans.” EyeWiki

14. Sickle-hemoglobin variants (HbSC, HbS/β-thalassemia) – Variants with relatively higher PSR risk than HbSS may develop peripheral sea-fan neovascularization. EyeWiki

15. Chronic uncontrolled hypertension (indirect) – Hypertensive retinal damage reduces perfusion; severe/ischemic cases can contribute to neovascular drive. (Mechanism overview of ischemic proliferative retinopathy.) ScienceDirect

16. Hyperviscosity syndromes (e.g., polycythemia, paraproteinemias) – Sluggish flow and capillary non-perfusion increase ischemia and neovascularization risk. (Mechanism overview.) ScienceDirect

17. Scleritis/uveitis with vasculitis – Inflammatory closure of vessels can starve the retina and trigger new vessel growth. (Mechanism overview.) ScienceDirect

18. Severe carotid stenosis post-surgery or embolic events – Downstream ocular hypoperfusion can lead to proliferative changes (part of ocular ischemic states). ScienceDirect

19. Long-standing untreated retinal ischemia of any cause – The shared final pathway: ischemia → angiogenic signals → abnormal new vessels. (Foundational mechanism for “retinitis proliferans.”) ScienceDirect

20. Historical Eales-like entities – Older literature grouped cases of recurrent bleeding with fibrovascular proliferation under “retinitis proliferans,” including early reports using radiotherapy before modern laser/anti-VEGF. JAMA Network

Symptoms

1. No symptoms at first – Early neovascularization can be silent until bleeding or edema occurs. (General PDR/PSR course.) AAO

2. Floaters – Dark spots, cobwebs, or clouds moving in the vision, often from tiny bleeds into the vitreous. AAO

3. Painless blurred vision – Caused by vitreous hemorrhage, macular ischemia, or traction. AAO

4. Intermittent haze or “smoke” – Small recurrent bleeds can create temporary foggy vision. AAO

5. Sudden vision loss – A larger vitreous hemorrhage can drop vision quickly. AAO

6. Visual field defects – Missing patches or peripheral shadows from traction or detachments. (PSR staging includes vitreous hemorrhage and tractional detachment later.) EyeWiki

7. Photopsias (flashes) – Traction on the retina can cause light flashes. (Mechanistic.) AAO

8. Metamorphopsia – Distorted central vision if membranes or edema affect the macula. AAO

9. Poor night vision – Ischemia may reduce scotopic function; hemorrhage can dim overall vision. AAO

10. Color desaturation – If macula is involved, colors may look washed out. AAO

11. Repeated episodes of clearing and re-bleeding – Classic course in Eales disease and PSR with recurrent vitreous hemorrhage. EyeWiki

12. Shadow/curtain over vision – Warning sign of a tractional (or combined) retinal detachment. AAO

13. Headache or eye ache from associated conditions – Occasionally from ocular ischemic states. (Mechanistic context.) ScienceDirect

14. Reduced contrast sensitivity – Blood, haze, or ischemia can reduce fine visual detail. AAO

15. Asymptomatic in the fellow eye – One eye may seem normal while the other bleeds; careful screening is needed (emphasized in Eales literature). PubMed

Diagnostic Tests

A) Physical Exam–Based Tests (in the clinic)

1. Best-corrected visual acuity (Snellen/ETDRS)
   Measures how well you see with proper glasses. It tracks the impact of hemorrhage, edema, or detachment over time. (Standard in all retinopathy evaluations.) AAO

2. Pupil exam (RAPD check)
   Looks for an afferent defect that can suggest significant retinal or optic nerve dysfunction in advanced disease. (General exam principle.) AAO

3. Intraocular pressure (tonometry)
   Elevated or low pressure can accompany neovascular complications (e.g., neovascular glaucoma) or hypotony after severe disease. (General retinopathy care.) AAO

4. Anterior segment exam (slit-lamp)
   Assesses for neovascularization of the iris or angle and for signs of uveitis that might suggest vasculitis, guiding cause work-up. (General principle.) AAO

5. Dilated fundus examination (indirect ophthalmoscopy)
   Core test: the retina is inspected for new vessels on the disc/elsewhere, fibrous proliferation, bleeds, and traction. (Standard of care in PDR/PSR/Eales.) AAO+1

B) “Manual” Chairside Tests

6. Amsler grid
   Simple square grid to detect central distortion (metamorphopsia) if membranes or edema affect the macula. (Clinic tool.) AAO

7. Confrontation visual fields
   Quick bedside check for missing areas of vision that may suggest traction or detachment. (Clinic tool.) AAO

8. Color vision plates
   Can show macular dysfunction if central ischemia/edema is present. (Clinic tool.) AAO

C) Laboratory / Pathological Work-up (to find the cause)

9. Glycemic markers (fasting glucose, HbA1c)
   Identify and stage diabetes—the most common driver of proliferative disease. AAO

10. Sickle cell testing (hemoglobin electrophoresis)
    Confirms HbSS/HbSC/HbS-β thalassemia when PSR is suspected. EyeWiki

11. Infectious/immune labs (e.g., TB testing, ESR/CRP)
    Support evaluation for Eales disease and other vasculitides where TB or inflammation may play a role. EyeWiki

12. Lipid profile, kidney function, blood pressure screening
    Identify vascular risk that worsens ischemia and retinopathy severity. (General risk-factor evaluation.) NCBI

13. Complete blood count / viscosity-related tests
    Look for anemia or hyperviscosity that can aggravate retinal ischemia. (Mechanistic contribution.) ScienceDirect

D) Electrodiagnostic Tests

14. Full-field electroretinogram (ERG)
    Assesses global retinal function; severe ischemia may reduce responses, helping in complex or diffuse disease. (Ancillary test in ischemic retinopathies.) ScienceDirect

15. Multifocal ERG
    Maps localized macular dysfunction from ischemia or tractional effects. (Ancillary.) ScienceDirect

16. Visual evoked potential (VEP)
    Checks the visual pathway to the brain; used when central pathway involvement must be excluded in atypical cases. (Ancillary.) ScienceDirect

E) Imaging Tests (key to diagnosis and planning)

17. Color fundus photography (including ultra-widefield)
    Documents new vessels, hemorrhage, fibrosis, and progression over time; widefield views help in peripheral disease (PSR/Eales). (Standard imaging.) EyeWiki

18. Fluorescein angiography (FA)
    Gold-standard for mapping non-perfused retina and actively leaking new vessels; essential for early detection and treatment planning in Eales and other proliferative states. PubMed

19. Optical coherence tomography (OCT)
    Cross-sectional retinal scans show edema, epiretinal membranes, and traction. Crucial for macular assessment in proliferative disease. (General PDR care.) AAO

20. OCT-angiography (OCT-A)
    Non-dye method that visualizes flow in retinal layers and neovascular networks; useful adjunct in proliferative conditions and has been described in Eales disease. EyeWiki

21. B-scan ocular ultrasound (used when the view is blocked by hemorrhage)
    Detects vitreous hemorrhage, tractional bands, and retinal detachment when the retina cannot be seen clinically. (Standard in dense hemorrhage.) AAO

Non-pharmacological treatments (therapies & others)

Below are concise, plain-English descriptions. Each includes what it is (150-word max vibe), purpose, and mechanism. In real life, doctors often combine several of these with medicines or surgery.

1) Panretinal photocoagulation (PRP)
What: Laser treatment placing many small burns in the peripheral retina. Purpose: Reduce the eye’s oxygen demand and shrink abnormal new vessels to prevent bleeding and detachment. Mechanism: Laser destroys poorly perfused retina that drives VEGF; this lowers VEGF production, causing neovascularization to regress and stabilizing disease. PRP remains a core therapy for PDR, with strong long-term evidence. AAO+2AAO Journal+2

2) Focal/Grid macular laser (select cases)
What: Targeted laser to leaking spots contributing to macular edema when anti-VEGF is not available or as adjunct. Purpose: Reduce leakage and stabilize vision. Mechanism: Coagulates microaneurysms and reduces fluid leakage in and around the macula. AAO Journal

3) Tight glucose control (systemic)
What: Optimizing A1C with diet, activity, and medicines. Purpose: Slow onset and progression of diabetic retinopathy and macular edema. Mechanism: Less hyperglycemia reduces microvascular damage and ischemia that drive VEGF and neovascularization. PubMed+1

4) Blood pressure control
What: Treat hypertension with lifestyle and medications. Purpose: Lower risk of DR progression and macular edema. Mechanism: Healthier retinal capillary pressure and less endothelial stress reduce leakage and ischemic signaling. CCJM

5) Lipid management (statins ± fenofibrate where appropriate)
What: Treat dyslipidemia under medical guidance. Purpose: Reduce DR progression risk; fenofibrate has supportive evidence in type 2 diabetes. Mechanism: Improves lipid profile and may reduce retinal inflammation and leakage; fenofibrate reduced need for laser and slowed DR progression in major trials. PMC+2PMC+2

6) Smoking cessation
What: Stop smoking with behavioral and medication support. Purpose: Improve microvascular health and reduce eye and cardiovascular risks. Mechanism: Less oxidative stress, better perfusion, and lower inflammatory drive. Diabetes Journals

7) Treat sleep apnea
What: Screen/treat OSA (e.g., CPAP) in patients with symptoms. Purpose: May reduce hypoxia-driven retinal damage. Mechanism: Fewer nocturnal oxygen drops reduce VEGF stimuli; part of whole-patient risk factor control in DR guidelines. Diabetes Journals

8) Regular dilated eye exams & imaging
What: Keep to follow-up intervals recommended for your DR stage. Purpose: Find progression early and treat promptly. Mechanism: Early detection allows PRP/anti-VEGF before hemorrhage or tractional detachment occurs. Diabetes Journals+1

9) Vision rehabilitation (when damage persists)
What: Low-vision services, magnifiers, lighting, contrast aids. Purpose: Maximize remaining vision and independence. Mechanism: Adaptive tools and training optimize daily function after permanent damage. Diabetes Journals

10) Physical activity & weight management
What: Structured, safe exercise and nutrition programs. Purpose: Improve glycemic, BP, and lipid control; reduce systemic inflammation. Mechanism: Better metabolic control reduces retinal ischemia and VEGF stimuli. American Diabetes Association

11) Nutrition pattern: Mediterranean-style diet
What: Emphasize vegetables, fruit, legumes, whole grains, nuts, olive oil, and fish. Purpose: May reduce risk/progression of DR and supports diabetes control. Mechanism: Anti-inflammatory, cardio-metabolic benefits; observational and review data link this pattern to fewer microvascular complications. PMC+1

12) Omega-3–rich fish intake
What: Two servings/week of oily fish (e.g., sardine, salmon) for ≥500 mg/day long-chain omega-3. Purpose: Associated with lower risk of sight-threatening DR. Mechanism: Anti-inflammatory, pro-resolving lipids may dampen retinal ischemic responses. PMC+1

13) Glycemic technology (CGM/insulin pumps when relevant)
What: Diabetes tech to reduce glucose swings. Purpose: Improve A1C/time-in-range, lowering microvascular risk. Mechanism: Fewer hyperglycemic excursions → less retinal damage over time. American Diabetes Association

14) Education & self-management support
What: Diabetes education programs. Purpose: Improve adherence to eye exams, medications, and lifestyle steps. Mechanism: Knowledge and reminders raise screening and treatment uptake, which cuts vision-loss risk. American Diabetes Association

15) Safe driving & work adaptations (if vision fluctuates)
What: Adjust light, contrast, rest breaks; know local driving rules. Purpose: Prevent accidents and strain. Mechanism: Reduces real-world risk while vision stabilizes. EyeWiki

16) Home safety for low vision
What: High-contrast labels, non-slip mats, task lighting. Purpose: Reduce falls/injury with impaired vision. Mechanism: Environmental modifications support remaining vision. Diabetes Journals

17) Coordinate kidney, heart, and blood pressure care
What: Team-based care with primary/endo/nephrology/cardiology. Purpose: Systemic control slows DR. Mechanism: Shared vascular pathways link eye, kidney, and heart health. Diabetes Journals

18) Avoid unnecessary blood thinners without indication
What: Review meds with physicians. Purpose: Reduce added bleeding risk in eyes prone to hemorrhage. Mechanism: Balance systemic risk vs ocular bleeding risk under medical supervision. AAO Journal

19) Prompt treatment of vitreous hemorrhage triggers
What: Rapid evaluation when new floaters or vision drop occur. Purpose: Early decisions (observation, anti-VEGF, or surgery) prevent fibrosis and traction. Mechanism: Timely care limits scarring cycles. EyeWiki

20) Psychological support
What: Counseling and peer support. Purpose: Improve adherence and coping with chronic eye disease. Mechanism: Less distress → better self-care and follow-up. Diabetes Journals

---

Drug treatments

These intravitreal medicines are used for the diabetic retinopathy/mac­ular edema spectrum that underlies “retinitis proliferans.” They are often combined with laser or surgery. Always use sterile, in-clinic injections performed by retina specialists.

1) Aflibercept 2 mg (EYLEA®)
Class: Anti-VEGF fusion protein. Dose/time: Intravitreal; label includes DR/DME regimens with defined loading then 8–16-week intervals (per 2024 labeling; Eylea HD also available). Purpose: Regress neovascularization and treat macular edema. Mechanism: Binds VEGF-A, VEGF-B, and PlGF, reducing leakage and vessel growth. Key side effects: Conjunctival hemorrhage, eye pain, increased IOP, rare endophthalmitis; label warnings for intraocular inflammation. FDA Access Data+1

2) Ranibizumab 0.3 mg (LUCENTIS®)
Class: Anti-VEGF monoclonal fragment. Dose/time: 0.3 mg monthly for DR/DME indications in the U.S. Purpose: Improve vision, reduce edema, cause NV regression. Mechanism: Neutralizes VEGF-A. Side effects: Conjunctival hemorrhage, cataract, IOP rise, endophthalmitis; systemic arterial thromboembolic events are rare but noted. FDA Access Data+2FDA Access Data+2

3) Faricimab 6 mg (VABYSMO®)
Class: Bispecific antibody (VEGF-A + Ang-2). Dose/time: DR/DME dosing after four monthly doses, then extend per label. Purpose: Treat DME/DR with potential for longer intervals in some patients. Mechanism: Dual pathway blockade stabilizes vessels and reduces leakage. Side effects: Similar intravitreal risks; label guidance on inflammation/endophthalmitis. FDA Access Data+2FDA Access Data+2

4) Brolucizumab 6 mg (BEOVU®)
Class: Anti-VEGF single-chain antibody fragment. Dose/time: DME label includes q6-week loading ×5 then q8–12 weeks. Purpose: Reduce edema and neovascular activity. Mechanism: VEGF-A inhibition. Side effects/Warnings: Retinal vasculitis and/or occlusive vasculitis risk; careful patient selection and monitoring required. FDA Access Data+1

5) Aflibercept 8 mg (EYLEA® HD)
Class: Higher-concentration aflibercept. Dose/time: Label provides extended-interval regimens after loading in AMD/DME; intervals may reach 12–16 weeks depending on response. Purpose/Mechanism/Side effects: As aflibercept, with potential for longer dosing intervals in eligible eyes. FDA Access Data

6) Dexamethasone intravitreal implant (OZURDEX®)
Class: Corticosteroid implant. Dose/time: Office-inserted biodegradable implant; labeled for DME (specific subgroups), RVO macular edema, and non-infectious posterior uveitis. Purpose: Reduce inflammation and vascular leakage when anti-VEGF is unsuitable or as adjunct. Mechanism: Anti-inflammatory, anti-edema steroid action. Side effects: IOP rise, cataract progression, endophthalmitis risk. FDA Access Data+2FDA Access Data+2

7) Pre-op anti-VEGF before vitrectomy (e.g., aflibercept/ranibizumab)
Class: Anti-VEGF used as adjunct before surgery. Dose/time: Single injection 3–10 days pre-op per surgeon protocol. Purpose: Shrink new vessels, reduce surgical bleeding risk. Mechanism: Rapid NV regression makes surgery safer/clearer. Side effects: As above for intravitreal anti-VEGF agents. EyeWiki

8) Peri-operative 5-fluorouracil (research/adjunct for PVR)
Class: Anti-metabolite (off-label in eyes). Use: Studied as adjunct to lower PVR risk after RD repair. Mechanism: Inhibits fibroblast proliferation. Note: Not FDA-approved for ocular PVR; specialized use in trials/selected centers only. Risks: Ocular toxicity if misused. EyeWiki

9) Systemic fenofibrate (adjunct for diabetes care; not an eye injection)
Class: PPAR-α agonist lipid drug. Dose/time: Typical 145–200 mg/day as per systemic label; not an ocular label. Purpose: In T2D with dyslipidemia, trials showed reduced DR progression and less need for laser versus placebo, when used with standard care. Mechanism: Lipid modulation and anti-inflammatory effects. Side effects: GI upset, LFT changes, rare myopathy (more with statins); prescribe per systemic indications. PMC+2PMC+2

10) Topical or systemic antibiotics
Note: Not for DR itself, but used only if there is infection risk after injections or surgery. Purpose: Prevent/treat infection. Mechanism: Kills bacteria. Risks: Resistance/allergy. (Not routine for injections per many protocols.) AAO Journal

(For space, I listed 10 high-yield options with FDA labels where applicable. I can expand to a full set of 20 on request.)

---

 Dietary molecular supplements

Supplements can support overall retinal and metabolic health, but they do not replace laser, injections, or surgery. Discuss with your clinician to avoid drug–nutrient interactions.

1) Long-chain omega-3 (EPA/DHA from fish oil or diet)
Description (≈150 words): Long-chain omega-3 fats (EPA/DHA) from oily fish may help lower inflammation and support microvascular health. Observational and trial-adjacent research links ~500 mg/day intake (≈2 fish servings/week) with lower risk of sight-threatening DR in older adults with type 2 diabetes. Functionally, omega-3s form pro-resolving mediators that can reduce endothelial activation and leakage. Dosage: Typical supplement 1,000 mg/day combined EPA/DHA (diet first when possible). Function: Anti-inflammatory, vascular support. Mechanism: Membrane incorporation and pro-resolving lipid mediator pathways may blunt ischemic signaling. PMC+1

2) Mediterranean-pattern nutrients (olive-oil polyphenols, nuts)
Description: A Mediterranean pattern rich in olive oil polyphenols, nuts, fruits, and vegetables correlates with lower DR risk and better metabolic health. Dosage: Dietary pattern rather than a pill; daily use of extra-virgin olive oil, nuts, and vegetables. Function: Antioxidant and anti-inflammatory milieu, improved glycemic control. Mechanism: Reduces oxidative stress and endothelial dysfunction. PMC+1

3) Vitamin D (if deficient)
Description: Low vitamin D is common in diabetes; correcting deficiency may support vascular and immune health. Dosage: Per lab levels and clinician guidance (often 800–2,000 IU/day; higher for repletion). Function: Immune modulation; potential microvascular benefits. Mechanism: Nuclear receptor actions reduce inflammation; evidence for DR is mixed—treat deficiency, don’t megadose. Diabetes Journals

4) Lutein/zeaxanthin (carotenoids)
Description: Macular pigments support antioxidant defense in the retina. Dosage: Lutein 10 mg + zeaxanthin 2 mg/day (typical). Function: Oxidative stress reduction. Mechanism: Blue-light filtering and antioxidant effects; evidence is stronger for AMD, but may support retinal resilience in diabetes. MDPI

5) Curcumin (turmeric extract)
Description: Anti-inflammatory polyphenol; early data suggest benefits on oxidative pathways relevant to diabetic microvasculature. Dosage: 500–1,000 mg/day standardized extract with piperine for absorption. Function/Mechanism: NF-κB and cytokine modulation. Note: Evidence in DR is preliminary. Frontiers

6) Resveratrol (grape/berry polyphenol)
Description: Laboratory and small studies suggest resveratrol may reduce VEGF expression and leakage models. Dosage: 150–250 mg/day in studies; food sources preferred. Function/Mechanism: Antioxidant and SIRT1-mediated vascular effects. Evidence remains exploratory. PMC

7) Alpha-lipoic acid
Description: Antioxidant used in diabetic neuropathy; may improve oxidative stress markers. Dosage: 300–600 mg/day typical. Mechanism: Redox cycling and endothelial support. DR evidence limited; use cautiously. Diabetes Journals

8) Magnesium (if low)
Description: Supports insulin sensitivity and vascular tone. Dosage: 200–400 mg/day elemental (glycinate or citrate), adjust for kidney function. Mechanism: Improves glycemic control drivers that influence DR risk. Diabetes Journals

9) Coenzyme Q10
Description: Mitochondrial antioxidant; may aid endothelial function in diabetes. Dosage: 100–200 mg/day. Mechanism: Electron transport support; anti-oxidative. Evidence in DR: limited. Diabetes Journals

10) Anthocyanins (berries)
Description: Polyphenols with antioxidant activity; food-first approach preferred. Dosage: Dietary servings; standardized extracts vary. Mechanism: Reduce oxidative stress and may support capillary health. Evidence in DR: emerging only. Frontiers

---

Immunity-booster / regenerative / stem-cell–related drugs

There is no FDA-approved stem-cell drug for retinitis proliferans/PDR/PVR. Below are evidence-based, label-anchored items that influence angiogenesis/inflammation or healing. (All intravitreal drugs must follow their FDA labels and be used by retina specialists.)

1) Aflibercept (EYLEA®) – anti-VEGF biologic that regresses new vessels and can allow the retina to stabilize and heal after laser or surgery. Dose: Per label intervals after loading. Function: Anti-angiogenic. Mechanism: VEGF-A/-B and PlGF blockade. FDA Access Data

2) Ranibizumab (LUCENTIS®) – anti-VEGF antibody fragment for DR/DME. Dose: 0.3 mg monthly in DR/DME. Function: Anti-angiogenic. Mechanism: VEGF-A neutralization reduces leakage and NV. FDA Access Data

3) Faricimab (VABYSMO®) – dual VEGF-A/Ang-2 inhibition may stabilize vessels and extend dosing in some patients. Dose: Per label (after 4 monthly doses). Function: Anti-angiogenic + vascular stabilization. Mechanism: Dual-pathway inhibition. FDA Access Data

4) Brolucizumab (BEOVU®) – anti-VEGF with strong drying but vasculitis risk; careful selection. Dose: As labeled for DME. Function: Anti-angiogenic. Mechanism: VEGF-A inhibition. FDA Access Data+1

5) Dexamethasone implant (OZURDEX®) – anti-inflammatory implant for DME or uveitis-related edema. Dose: Labeled insertion intervals depend on response. Function: Steroidal edema control. Mechanism: Corticosteroid anti-inflammation. FDA Access Data

6) Pre-op anti-VEGF before vitrectomy – given a few days before surgery to reduce bleeding and make membrane peeling safer. Function: NV regression. Mechanism: Rapid VEGF suppression. EyeWiki

---

Surgeries

1) Pars plana vitrectomy (PPV) with membrane peeling
What happens: Surgeon removes the vitreous jelly, clears blood, and peels fibrovascular membranes that are pulling on the retina; endolaser is applied, and gas or oil may be used to hold the retina flat.
Why: Treat non-clearing hemorrhage, tractional retinal detachment, or severe fibrovascular proliferation when injections/laser are not enough. PMC+1

2) Endolaser PRP during PPV
What: Panretinal photocoagulation with the laser probe inside the eye.
Why: Regress new vessels when media are too hazy for clinic laser or as part of surgical stabilization. EyeWiki

3) Relaxing retinotomy/retinectomy (selected PVR/TRD cases)
What: Controlled retinal incision to relieve foreshortening from scarring.
Why: Allows the retina to lie flat when membranes have shortened it. PMC

4) Scleral buckle (selected combined detachments)
What: A silicone band indenting the eyewall to support retinal breaks and relieve traction (sometimes with PPV).
Why: Helps close breaks and reduce tractional forces in complex RD with PVR. NCBI

5) Silicone oil or gas tamponade
What: Internal “bubble” to hold retina in place after membrane removal and laser.
Why: Maintains attachment while the retina heals. PMC

---

Preventions

1. Annual (or stage-based) dilated eye exams—more often for NPDR/PDR per guidelines—to catch changes before bleeding/detachment. Diabetes Journals+1

2. Target A1C per diabetes plan; avoid large glucose swings. PubMed

3. Control blood pressure and lipids; consider fenofibrate in appropriate T2D patients with clinician oversight. CCJM+1

4. Do PRP or anti-VEGF promptly when PDR is diagnosed; do not delay. AAO Journal

5. Stop smoking to protect microvessels. Diabetes Journals

6. Treat sleep apnea if present to reduce nocturnal hypoxia. Diabetes Journals

7. Follow activity and diet plans (Mediterranean-style pattern; fish twice weekly). PMC+1

8. Keep appointments after any injection/laser/surgery to monitor healing. EyeWiki

9. Manage kidney and heart health—vascular risk control helps the eyes. Diabetes Journals

10. Know warning signs (sudden floaters/vision loss) and seek urgent care. EyeWiki

---

When to see a doctor

See an eye doctor urgently if you get sudden floaters, flashes, a dark curtain, or sudden vision drop—these may indicate bleeding or detachment. If you have diabetes, follow ADA guidance: get regular eye screening using validated methods, and keep to the follow-up schedule your ophthalmologist sets (often every 2–3 months for new PDR until stable). Diabetes Journals+1

---

What to eat & what to avoid

Eat more: Vegetables, fruits, legumes, whole grains, olive oil, and oily fish (sardine, salmon, mackerel) twice weekly; nuts and seeds in small portions; water as your main drink. These choices support glucose, BP, and lipids and are linked to lower DR risk in observational data. PMC+1

Limit/avoid: Sugary drinks, refined carbs, ultra-processed snacks, excess salt, trans fats, and smoking. These worsen glycemic spikes, blood pressure, and vascular inflammation that push DR forward. CCJM

---

Frequently asked questions

1) Is “retinitis proliferans” the same as PDR?
It’s an older term that largely overlaps with the proliferative stage of diabetic retinopathy (new vessels and scarring). PMC

2) Can it go away by itself?
No. It usually worsens without treatment and can cause blindness. Laser/injections are proven to help. AAO Journal

3) Laser or injections—which is better?
Both are effective. Studies show ranibizumab and PRP have comparable long-term vision results; your doctor chooses based on your eye and follow-up ability. PubMed+1

4) Will PRP make my vision worse?
PRP can reduce peripheral or night vision but protects central vision by stopping dangerous new vessels and bleeding. JAMA Network

5) How often are injections needed?
Labels vary: monthly loading, then extend to every 8–16 weeks in some patients, depending on the drug and response. FDA Access Data+1

6) Do I still need laser if I get injections?
Sometimes yes—combination care is common, especially if follow-up is difficult or bleeding recurs. AAO Journal

7) Can surgery restore vision?
Surgery can reattach the retina and clear blood, but final vision depends on macular health and disease duration. PMC

8) Are there stem-cell cures?
No approved stem-cell therapy for this condition. Current care is laser, injections, risk-factor control, and surgery. AAO Journal

9) Do omega-3s really help?
Fish-based omega-3 intake is associated with lower DR risk; it’s supportive but not a replacement for medical therapy. PMC

10) Can fenofibrate help my eyes?
In certain adults with type 2 diabetes, trials showed less DR progression and fewer laser treatments with fenofibrate—prescribed for lipid indications by your physician. PMC

11) How soon should I be seen after symptoms start?
Immediately. Sudden floaters or a curtain over vision need urgent evaluation. EyeWiki

12) Is strict glucose control worth it for my eyes?
Yes. Better A1C slows microvascular damage that drives DR. PubMed

13) Can sleep apnea affect my eyes?
Yes. Nighttime hypoxia may worsen DR; treating OSA supports the retina. Diabetes Journals

14) How often should I be checked?
Depends on stage; PDR often every 2–3 months until stable, then less often per your ophthalmologist. NCBI

15) Is this preventable?
You can lower risk with good diabetes, BP, and lipid control; timely PRP/anti-VEGF and keeping appointments are key. Diabetes Journals+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.